Dyne Therapeutics Files 8-K with Material Agreement
Ticker: DYN · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $18.44, $17.3336, $328.5 m, $377.9 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-K, filing
TL;DR
Dyne Therapeutics signed a big deal, filing an 8-K today.
AI Summary
On December 9, 2025, Dyne Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing. The principal executive offices are located at 1560 Trapelo Road, Waltham, Massachusetts.
Why It Matters
This filing indicates a significant development for Dyne Therapeutics, potentially involving new partnerships, acquisitions, or other material contracts that could impact its business operations and future prospects.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not detailed in the provided excerpt, necessitating further investigation.
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — Registrant
- December 9, 2025 (date) — Date of earliest event reported
- 1560 Trapelo Road, Waltham, Massachusetts (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Dyne Therapeutics, Inc. on December 9, 2025?
The provided excerpt does not specify the details of the material definitive agreement, only that one was entered into on December 9, 2025.
What other events are reported in this 8-K filing by Dyne Therapeutics, Inc.?
The filing indicates 'Other Events' are reported, but the specifics are not detailed in the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing states that 'Financial Statements and Exhibits' are included, but their content is not described in the excerpt.
Where are Dyne Therapeutics, Inc.'s principal executive offices located?
Dyne Therapeutics, Inc.'s principal executive offices are located at 1560 Trapelo Road, Waltham, Massachusetts, 02451.
What is the SEC file number for Dyne Therapeutics, Inc.?
The SEC file number for Dyne Therapeutics, Inc. is 001-39509.
Filing Stats: 1,653 words · 7 min read · ~6 pages · Grade level 14.7 · Accepted 2025-12-10 16:22:33
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share DYN Nasdaq Glob
- $18.44 — ing price of the Underwritten Shares is $18.44 per share, and the Underwriters have ag
- $17.3336 — he Underwriting Agreement at a price of $17.3336 per share. Under the terms of the Under
- $328.5 m — from the Offering will be approximately $328.5 million, or approximately $377.9 million
- $377.9 million — mately $328.5 million, or approximately $377.9 million if the Underwriters exercise in full th
- $50.0 million — cluding the second term loan tranche of $50.0 million that the Company borrowed under its Loa
Filing Documents
- d76666d8k.htm (8-K) — 35KB
- d76666dex11.htm (EX-1.1) — 218KB
- d76666dex51.htm (EX-5.1) — 9KB
- d76666dex991.htm (EX-99.1) — 9KB
- g76666g1210084131832.jpg (GRAPHIC) — 2KB
- g76666g1210084152347.jpg (GRAPHIC) — 3KB
- g76666g1210085520386.jpg (GRAPHIC) — 5KB
- 0001193125-25-314249.txt ( ) — 463KB
- dyn-20251209.xsd (EX-101.SCH) — 3KB
- dyn-20251209_lab.xml (EX-101.LAB) — 17KB
- dyn-20251209_pre.xml (EX-101.PRE) — 11KB
- d76666d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: December 10, 2025 By: /s/ John G. Cox Name: John G. Cox Title: President and Chief Executive Officer